Article
Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease.
Cancer chemotherapy and pharmacology - 1 Mar 2010
Fukui Tomoya, Otani Sakiko, Hataishi Ryuji, Jiang Shi-Xu, Nishii Yasuto, Igawa Satoshi, Mitsufuji Hisashi, Kubota Masaru, Katagiri Masato, Masuda Noriyuki
Abstract excerpt
Small-molecule tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) pathways are used clinically for patients with non-small cell lung cancer (NSCLC). It is well established that somatic mutations in the kinase domain of the EGFR (Lynch et al. in N Engl J Med 350:2129-2139, 2004; Paez et al. in Science 304:1497-1500, 2004) are strongly associated with the tumor response and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.